Literature DB >> 27183096

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

T N Trahair1,2,3, R B Lock2,3, R Sutton2,3, K C S Sia2,3, K Evans2, J Richmond2, T Law2, N C Venn2, J A Irving4, S Moore5, E Nievergall6,7, P Dang6, S L Heatley6,7, D L White6,7,8, T Revesz8,9.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27183096     DOI： 10.1038/bmt.2016.122

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.

Authors:  Marian Case; Elizabeth Matheson; Lynne Minto; Rosline Hassan; Christine J Harrison; Nick Bown; Simon Bailey; Josef Vormoor; Andrew G Hall; Julie A E Irving
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

2.  Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Authors:  Brent W Weston; Melissa A Hayden; Kathryn G Roberts; Susan Bowyer; Johann Hsu; George Fedoriw; Kathleen W Rao; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

3.  Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment.

Authors:  Maike Schmitz; Petra Breithaupt; Nastassja Scheidegger; Gunnar Cario; Laura Bonapace; Barbara Meissner; Paulina Mirkowska; Joelle Tchinda; Felix K Niggli; Martin Stanulla; Martin Schrappe; Andre Schrauder; Beat C Bornhauser; Jean-Pierre Bourquin
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

4.  The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Authors:  Hernan Carol; Barbara Szymanska; Kathryn Evans; Ingrid Boehm; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2013-02-20       Impact factor: 12.531

5.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

Authors:  M Eapen; S A Giralt; M M Horowitz; J P Klein; J E Wagner; M-J Zhang; M S Tallman; D I Marks; B M Camitta; R E Champlin; O Ringdén; C N Bredeson; R Martino; R P Gale; M S Cairo; M R Litzow; M deLima
Journal:  Bone Marrow Transplant       Date:  2004-10       Impact factor: 5.483

6.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

7.  Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.

Authors:  Nobuko Hijiya; Clinton F Stewart; Yinmei Zhou; Dario Campana; Elaine Coustan-Smith; Gaston K Rivera; Mary V Relling; Ching-Hon Pui; Amar Gajjar
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

8.  Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

Authors:  Peter Bader; Hermann Kreyenberg; Günter H R Henze; Cornelia Eckert; Miriam Reising; Andre Willasch; Andrea Barth; Arndt Borkhardt; Christina Peters; Rupert Handgretinger; Karl-Walter Sykora; Wolfgang Holter; Hartmut Kabisch; Thomas Klingebiel; Arend von Stackelberg
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

9.  Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

Authors:  Barbara Szymanska; Urszula Wilczynska-Kalak; Min H Kang; Natalia L M Liem; Hernan Carol; Ingrid Boehm; Daniel Groepper; C Patrick Reynolds; Clinton F Stewart; Richard B Lock
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

10.  Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse.

Authors:  Emmanuelle Clappier; Bastien Gerby; François Sigaux; Marc Delord; Farah Touzri; Lucie Hernandez; Paola Ballerini; André Baruchel; Françoise Pflumio; Jean Soulier
Journal:  J Exp Med       Date:  2011-04-04       Impact factor: 14.307
View more
  4 in total

1.  Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Authors:  Luke Jones; Jennifer Richmond; Kathryn Evans; Hernan Carol; Duohui Jing; Raushan T Kurmasheva; Catherine A Billups; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2017-01-24       Impact factor: 12.531

2.  Protocol for the avatar acceptability study: a multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New Zealand.

Authors:  Claire E Wakefield; Emma L Doolan; Joanna E Fardell; Christina Signorelli; Veronica F Quinn; Kathy F Tucker; Andrea F Patenaude; Glenn M Marshall; Richard B Lock; Gabrielle Georgiou; Richard J Cohn
Journal:  BMJ Open       Date:  2018-08-08       Impact factor: 2.692

3.  A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.

Authors:  Jad El-Hoss; Duohui Jing; Kathryn Evans; Cara Toscan; Jinhan Xie; Hyunjoo Lee; Renea A Taylor; Mitchell G Lawrence; Gail P Risbridger; Karen L MacKenzie; Rosemary Sutton; Richard B Lock
Journal:  Oncotarget       Date:  2016-09-13

4.  The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care.

Authors:  C E Wakefield; E L Doolan; J E Fardell; C Signorelli; V F Quinn; K M Tucker; A F Patenaude; G M Marshall; R B Lock; G Georgiou; R J Cohn
Journal:  EBioMedicine       Date:  2018-10-29       Impact factor: 8.143
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.